Sign In
Last checked at 
26 May 2016 14:00
FOR IMMEDIATE RELEASE 26 MAY 2016
2016 ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED
LUPUZOR™ SYMPOSIUM: 8 & 9 JUNE 2016
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed. A summary of proxy votes is shown in the table below. Please also refer to the 'Notice of the 2016 Annual General Meeting' in the Report & Accounts - 31 December 2015 (page 60).
RESOLUTION | FOR + DISCRETION | % | AGAINST | % | WITHHELD |
1 | 42,327,430 | 99.90 | 40,400 | 0.10 | 25,000 |
2 | 42,307,657 | 99.86 | 60,173 | 0.14 | 25,000 |
3 | 42,352,430 | 99.90 | 40,400 | 0.10 | 0 |
4 | 42,352,430 | 99.90 | 40,400 | 0.10 | 0 |
5 | 42,344,328 | 99.89 | 48,502 | 0.11 | 0 |
Special Resolution6 | 42,327,503 | 99.87 | 53,502 | 0.13 | 11,825 |
Lupuzor Symposium : Key Presenter : Prof. Sylviane Muller
As announced at the recent Preliminary Results, a Lupuzor™ Symposium is being hosted where Prof. Muller, inventor of Lupuzor™ will present on the unique 'Mechanism of Action' of Lupuzor™, also known by its chemical name 'Forigerimod' or 'P140'. Prof. Muller will also provide further evidence of the role the P140 molecule can take in the potential treatment of other autoimmune diseases.
Investor meetings as part of this Symposium are being held on both days. A sell-side analyst and media briefing will be held on 9 June @ 11:00 am at 50 Basinghall Street, EC2. For more information or if you would like to attend one of the briefings, please email: lisa.baderoon@immupharma.com.
For further information please see the Company's web site, www.immupharma.org, or contact:
-Ends-
For further information please contact:
|
Notes to Editors
ImmuPharma PLC
ImmuPharma is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma is led by a commercially focused Board and management team with extensive experience.
ImmuPharma announced on 1 March 2016 the successful completion of a £8.4 million fund raise, comprising a Placing and Subscription together with confirmation of EIS and VCT qualifying status. Monies raised will principally be used to complete the pivotal Phase III trial of Lupuzor™. Following the issue of the New Ordinary Shares ImmuPharma has 121,781,219 ordinary shares of 10 pence each (the "Ordinary Shares") in issue.
Lupuzor™
Lupuzor™ (also referred to as Forigerimod, or P140) is ImmuPharma's lead compound and a potential treatment for lupus (or Systemic Lupus Erythematosus), a chronic, potentially life-threatening auto-immune disease. Lupuzor™ has a novel mechanism of action aimed at modulating the body's immune system so that it does not attack healthy cells, and avoids causing adverse side effects. It has the potential to halt the progression of the disease in a substantial proportion of patients.
Lupuzor™ has been granted Fast Track status by the US FDA and approval to start Phase III under Special Protocol Assessment (SPA). This SPA was subsequently amended due to its strong safety and efficacy profile to allow for a reduced number of patients in the pivotal Phase III trial thereby reducing the projected cost and time of development considerably.
The pivotal Phase III clinical study is entitled "A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus". It is a pivotal study designed to demonstrate the safety and efficacy of IPP-201101 and as a last step prior to the filing of the drug for approval with the US Food & Drug Administration ("FDA") and the European Medicines Agency ("EMA"). For more information please visit: www.ClinicalTrials.gov/lupuzor
Commercial Opportunity
There are an estimated five million people globally suffering from Lupus, with approximately 1.5 million patients in the US, Europe and Japan (Source: Lupus Foundation of America). Current 'standard of care' treatments, including steroids and immunosuppressants, can potentially have either serious side effects for patients or limited effectiveness, with over 60% of patients not adequately treated. GSK's Benlysta is the first Lupus drug approved in over 50 years and paves the path to market for Lupuzor™. Based on conservative estimates, and taking into account that Benlysta is priced currently at approximately $35,000 per patient per year, Lupuzor™ would be entering a market with the potential for multi-billion dollar sales. For more information on Lupuzor™ please visit: www.lupuzor.com
Follow the stocks
